How one company profited while delaying Narcan's drugstore debut

The push to make the lifesaving opioid overdose antidote easier to buy took five years and multiple court battles, fueling worries about access and supply.

Related Keywords

Alleghany County ,Virginia ,United States ,Illinois ,Idaho ,Finland ,Lightlake ,Michigan ,New York ,Chicago ,Texas ,Salt Lake City ,Utah ,Washington ,Julie Stampler ,Robert Califf ,Eric Karas ,Matt Hartwig ,Joshua Sharfstein ,Robert Kramer ,Ainsley Bryce ,Jack Fishman ,Michael Hufford ,Nabarun Dasgupta ,Danielj Abdun Nabi ,Ginny Atwood Lovitt ,Maya Doe Simkins ,Michael Potestio ,Brandeis University Opioid Policy Research Collaborative ,Substance Use Disorder Task ,Washington Post ,Chicago Recovery Alliance ,Endo Pharmaceuticals ,Mental Health Services Administration ,Injury Prevention Research Center ,Pfizer ,University Of North Carolina At Chapel Hill ,Centers For Disease ,Texasam University ,Chris Atwood Foundation ,Opioid Crisis Response Advisory Council ,Idaho Office Of Drug ,Strategic National ,Drug Administration ,Illinois Department Of Human Services ,Emergent Biosolutions ,Jennifer Plumb ,Remedy Alliance ,Direct Relief ,North Carolina ,Chapel Hill ,Disease Control ,New York City ,Traci Green ,Brandeis University ,Opioid Policy Research ,Lightlake Therapeutics ,Adapt Pharma ,Substance Abuse ,Idaho Office ,Drug Policy ,Illinois Department ,Human Services ,Joy Alonzo ,More Narcan Please ,Narcan Please ,Harm Reduction Therapeutics ,Harm Reduction ,